Inmune Stock Buy Hold or Sell Recommendation


USD 8.77  0.07  0.79%   

Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Inmune Bio is 'Strong Buy'. Macroaxis provides Inmune Bio buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding INMB positions. The advice algorithm takes into account all of Inmune Bio's available fundamental, technical, and predictive indicators you will find on this site.
The advice is provided from Inmune Bio's buy-and-hold perspective. Please see Inmune Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Inmune and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Inmune Bio.

Execute Inmune Bio Buy or Sell Advice

The Inmune recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Inmune Bio. Macroaxis does not own or have any residual interests in Inmune Bio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Inmune Bio's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Inmune BioBuy Inmune Bio
Strong Buy


Somewhat reliableDetails

Hype Condition

Over hypedDetails

Current Valuation


Odds of Distress


Economic Sensitivity

Actively responds to the marketDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)


Financial Leverage


Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Inmune Bio has a Risk Adjusted Performance of 0.0483, Jensen Alpha of 0.4862, Total Risk Alpha of 1.01, Sortino Ratio of 0.0586 and Treynor Ratio of 0.1008
We provide advice to complement the regular expert consensus on Inmune Bio. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Inmune Bio is not overpriced, please check out all Inmune Bio fundamentals, including its cash and equivalents, cash flow from operations, and the relationship between the gross profit and debt to equity . Given that Inmune Bio has a price to book of 1.77 X, we strongly advise you to confirm Inmune Bio market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Inmune Bio Trading Alerts and Improvement Suggestions

Inmune Bio has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 181 K. Net Loss for the year was (30.34 M) with profit before overhead, payroll, taxes, and interest of 181 K.
Inmune Bio currently holds about 74.81 M in cash with (28.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.19.
Inmune Bio has a frail financial position based on the latest SEC disclosures
Roughly 35.0% of the company shares are held by company insiders
Latest headline from INmune Bio USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases - Form 8-K -

Inmune Bio current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price22.33
Target Median Price22.00
Target High Price31.00
Recommendation Mean1.70
Number Of Analyst Opinions3
Target Low Price14.00
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Inmune Bio Returns Distribution Density

The distribution of Inmune Bio's historical returns is an attempt to chart the future uncertainty of Inmune Bio's future price movements. The chart of the probability distribution of Inmune Bio stock daily returns describes the distribution of returns around its average expected value. We use Inmune Bio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Inmune Bio returns is essential to provide solid investment advice for Inmune Bio stock.
Mean Return0.18Value At Risk-8.48
Potential Upside11.04Standard Deviation6.22
 Return Density 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Inmune Bio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Inmune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Inmune Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inmune Bio backward and forwards among themselves. Inmune Bio's institutional investor refers to the entity that pools money to purchase Inmune Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares553.6 K4.7 M
Morgan StanleyCommon Shares300.5 K2.5 M
Janney Montgomery Scott LlcCommon Shares260.7 K2.2 M
Blackrock IncCommon Shares232 KM
Act Capital Management LlcCommon Shares230.5 K1.9 M
Geode Capital Management LlcCommon Shares127.5 K1.1 M
Deutsche Bank AgCommon Shares106 K893 K
Citadel Advisors LlcCall Options28.9 K243 K
Citadel Advisors LlcPut Options24.7 K208 K
Note, although Inmune Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Inmune Bio Cash Flow Accounts

201720182019202020212022 (projected)
Net Cash Flow or Change in Cash and Cash Equivalents1.23 M(1.18 M)6.81 M14.97 M52.84 M57.01 M
Issuance Purchase of Equity Shares2.06 M900 K12.21 M23.89 M81.41 M87.83 M
Net Cash Flow from Financing2.06 M900 K12.21 M23.89 M96.36 M103.96 M
Net Cash Flow from Operations(761.83 K)(2.06 M)(5.38 M)(8.94 M)(28.5 M)(29.25 M)
Effect of Exchange Rate Changes on Cash34.89 K(25.51 K)(15.04 K)19 K(10 K)(10.26 K)

Inmune Bio Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Inmune Bio or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Inmune Bio stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Inmune stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW1.66
Overall volatility
Information ratio 0.06

Inmune Bio Volatility Alert

Inmune Bio is displaying above-average volatility over the selected time horizon. Investors should scrutinize Inmune Bio independently to ensure intended market timing strategies are aligned with expectations about Inmune Bio volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inmune Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inmune Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Inmune Bio Implied Volatility

Inmune Bio's implied volatility exposes the market's sentiment of Inmune Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inmune Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inmune Bio stock will not fluctuate a lot when Inmune Bio's options are near their expiration.

Inmune Bio Fundamentals Vs Peers

Comparing Inmune Bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Inmune Bio's direct or indirect competition across all of the common fundamentals between Inmune Bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Inmune Bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Inmune Bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Inmune Bio by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare Inmune Bio to competition
FundamentalsInmune BioPeer Average
Return On Equity(51.00) %(0.31) %
Return On Asset(25.92) %(0.14) %
Current Valuation74.75 M16.62 B
Shares Outstanding17.84 M571.82 M
Shares Owned by Insiders34.96 %10.09 %
Shares Owned by Institutions14.56 %39.21 %
Number of Shares Shorted1.25 M4.71 M
Price to Earning(7.51) X28.72 X
Price to Book1.77 X9.51 X
Price to Sales864.56 X11.42 X
Revenue181 K9.43 B
Gross Profit181 K27.38 B
EBITDA(8.28 M)3.9 B
Net Income(30.34 M)570.98 M
Cash and Equivalents74.81 M2.7 B
Cash per Share4.19 X5.01 X
Total Debt15.23 M5.32 B
Debt to Equity0.19 %48.70 %
Current Ratio18.95 X2.16 X
Book Value Per Share4.95 X1.93 K
Cash Flow from Operations(28.5 M)971.22 M
Short Ratio9.78 X4.00 X
Earnings Per Share(1.59) X3.12 X
Number of Employees1018.84 K
Market Capitalization156.49 M19.03 B
Total Asset21.66 M29.47 B
Retained Earnings(21.84 M)9.33 B
Working Capital7.66 M1.48 B
Current Asset8.38 M9.34 B
Current Liabilities721.01 K7.9 B
Z Score4.68.72
   Purchase by Tesi Raymond Joseph of 6300 shares of Inmune Bio [view details]

About Inmune Bio Buy or Sell Advice

When is the right time to buy or sell Inmune Bio? Buying financial instruments such as Inmune Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Although Inmune Bio investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2019 2020 2021 2022 (projected)
Accounts Payable692.09 K1.55 M3.81 M4.11 M
Receivables568.14 K1.69 M4.91 M5.3 M

Use Investing Ideas to Build Portfolios

In addition to having Inmune Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Electronics Thematic Idea Now

Electronics Theme
Companies manufacturing electronic appliances and goods. The Electronics theme has 13 constituents.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
View All  Next Launch Electronics
Please see Inmune Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
157.4 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.